With a 846-bed Strong Memorial Hospital, Eastman Institute for Oral Health, and the University of Medicine and Dentistry, Medical Faculty Group, and School of Nursing, the URMC currently has over a 3,000 person research staff working on over 1,000 ongoing clinical trials related to cancer, heart disease, Parkinson's and pandemic influenza, among other diseases.
Since April 2019, the sponsors who wish to discuss new clinical trials can reach URMC through Trial Connect, a TriNetX service, and they are directly connected to the center's investigators.
Professor of Medicine and Public Health Sciences at UMRC, Martin Zand, said that TriNetX has presented clinical trials that ‘exactly matched’ the center’s primary areas of therapeutic interest.
Patricia Ames, director of URMC's Office of Clinical Research told us that the academic medical center already receives 'multiple queries per week'.
"So far, we are considering opening studies that originated from the TriNetX platform in dentistry, ophthalmology and neurology indications," Ames added.
Global expansion
TriNetX network of health care organization partnerships spans across 23 countries and thousands of sites. Data providers within the network cover 99% of US health plays and represent over 300 million patients.
The network has been used, according to the company, to analyze over 16,000 protocols and has presented over 4,190 clinical trial opportunities to its health care organization partners.
TriNetX has been expanding globally during the past few months. On March, it closed a series D financing round, receiving a total fund of $102m. Its customer base includes 29 pharmaceutical companies, such as Pfizer, Novartis and Sanofi.
